Purpose Drug safety classifications give a very basic estimation of risk and should only be used as general guideline when assessing risk of pregnancy-related drug exposure or planning treatment. We conducted a study to assess the strength of association between both the clinical pharmacologists' risk assessment and the FDA risk categorization, and adverse pregnancy outcomes. Methods We retrospectively reviewed records of 1,076 patients consecutively referred to the clinical pharmacology outpatient clinic for pregnancy-related drug exposure (2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008). Clinical pharmacologists' risk assessments were reviewed in relation to FDA drug categorization and available pregnancy outcomes. Results Overall, clinical pharmacologists' risk estimation was in agreement with the FDA risk categorization system in only 28% of consulted women, and in only 9% of women with high-risk exposure (FDA DX). Clinical pharmacologists' risk assessment confirming high-risk drug exposure had a better positive predictive value for adverse pregnancy outcomes than the FDA DX categorization (25% vs 14% respectively), while the negative predictive values were similar (92% vs 94% respectively). Clinical pharmacologists' risk assessment was a better predictor of adverse pregnancy outcomes compared with FDA risk categorization (OR 2.11 [95%CI 1.5-3.1; p<0.001] vs OR 1.52 [95%CI 1.1-2.1; p=0.014] respectively).
Introduction
The estimated prevalence of birth defects in the general population is 2-4% [1] . It is claimed that this prevalence is mainly independent of drug use in pregnancy, with less than 1% of birth defects thought to be attributable to maternal drug use [2] . Nevertheless, there is much fear about prescribing drugs in pregnant women, making underprescribing as much a concern as overprescribing. Several studies have explored the prevalence of drug prescription in pregnant women, with a wide range of results from 19% to more than 90% of pregnant women receiving at least one drug during pregnancy [3] [4] [5] [6] . As approximately 50% of pregnancies are unplanned, often drug exposure occurs in the early and most vulnerable stage of pregnancy [7] . Therefore, risk classification systems have been set up to summarise the available data on drug safety during pregnancy and to help in the assessment of the risks of pregnancy-related drug exposure and the balancing of benefits and risks when prescribing drugs in pregnant women. One of the most frequently used is the US Food and Drug Administration (FDA) pregnancy risk categorisation, which places the drug in one of five categories (A, B, C, D and X) according to the level of risk to the infant [8] . However, it is important to understand that drug safety classifications give a very basic estimation of risk and should only be used as general guidelines when planning treatment [9] , and that there are inconsistencies between various drug classifications, which can be a source of great confusion among users of these classification systems [10] . Although the FDA has announced the replacement of the present risk classification system with a narrative framework in order to ease informed counselling on drug safety in pregnancy, the pregnancy risk categories are still in effect and are still being used by physicians [11] . Since Croatia has not established its own risk classification system, the FDA risk classification system is still the most commonly used system in Croatia, due to its accessibility to prescribers through the Croatian Drug Registry [12] and the Croatian Pharmacotherapeutic Formulary [13] .
However, risk assessments must always be made on an individual basis, and the dose, route, duration and gestational timing of the exposure must also be taken into consideration in each case. Both underestimation and overestimation of risk must be avoided, and pregnant women with conditions requiring treatment must be treated adequately. Although their medical training predisposes clinical pharmacologists to a significant role in the area of drug use during pregnancy, this is probably the least developed area of clinical pharmacology.
There is a lack of organised information services on drug safety during pregnancy in Croatia; information is mostly available through some hospital Departments of Paediatrics, Gynaecology or Clinical Pharmacology. There is only one office in Croatia (Genetic Counselling with Teratogen Information Service) that is part a of European Network of Teratology Information Services (ENTIS), which includes 12 European and 2 non-European countries with the objective of coordinating the activities of different Teratology Information Services [14] . Similarly, counselling of patients and health care providers about exposure related to pregnancy and breastfeeding in North America is provided through the Organization of Teratology Information Services (OTIS) [15] .
Consultations on drug use during pregnancy have a 20-year-old tradition at our unit. When consulting women on risks of drug exposure or therapy planning during pregnancy, we too use the FDA risk categorisation system as well as the Australian Drug Evaluation Committee's categorisation [16] ; however, only as general guidance. To the best of our knowledge, there are no studies that examine the proportion of agreement between a classification system and a clinical pharmacologist's (or other experts') risk assessment of pregnancy-related drug exposure, which also includes the evaluation of these differences in relation to pregnancy outcomes. In one study that similarly compared the differences in advice on drug safety in pregnancy between product monographs and Drug Information Centres in Norway, no data on pregnancy outcomes were available [17] .
With these objectives in mind we conducted this study hoping to provide a clearer assessment of the value of the FDA risk classification and clinical pharmacologists' consultation in relation to adverse pregnancy outcomes caused by medication use.
Materials and methods

Study design and patient population
The Division of Clinical Pharmacology at the University Hospital Zagreb comprises a ward (11 beds), a clinical research unit and an outpatient clinic. The clinical pharmacology outpatient clinic serves patients with various pharmacotherapeutical problems. Approximately 20% of patients at the outpatient clinic are referred for consultation on drug use in pregnancy. During the patients' visit, demographic data, data on concomitant diseases, reasons for referral, habits (smoking, alcohol consumption), previous pregnancies, prescribed medications and indications for their prescription are collected by the use of a structured questionnaire. For every patient advised, a written clinical pharmacologist's expert opinion is prepared with a risk estimation concerning the individual patient's characteristics and indications for drug treatment, and is sent by post within 2-3 days to the referring physician and/or the patient's home address (when requested). Where appropriate, a final risk assessment is made with recommendations for the continuation, reassessment or discontinuation of therapy. Approximately 9-12 months after the consultation counselled patients are contacted by telephone or post (where the telephone number was not available) in order to obtain information on the pregnancy outcomes.
We retrospectively reviewed the records of 1,144 consecutively referred patients during a 9-year period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) . Clinical pharmacologists' risk assessments of patients were reviewed in relation to the FDA drug categorisation and available pregnancy outcomes. This study included only patients referred for consultation on pregnancy-related drug exposure. Pregnancy outcomes were available for 516 patients. Prior to data analysis of adverse pregnancy outcomes, we excluded cases of induced abortions (46 cases) and exposure to medications not classified by the FDA risk classification system (5 cases); 465 pregnancy outcomes were available for further analysis. Adverse pregnancy outcomes included were: spontaneous abortion, malformations, and other complications during pregnancy (preterm birth, perinatal complications possibly related to medication use).
FDA pregnancy risk classification and risk assessment
All drugs prescribed to a patient during pregnancy were classified according to the FDA risk classification. Since the FDA categorisation scheme classifies drugs into one of five major categories according to the potential fetal risk (A, B, C, D and X), we converted it into a numerical rating scale (NRS; 1, 2, 3, 4 and 5). Similarly, the final clinical pharmacologists' risk assessments were also converted into the same numerical scale thus allowing further comparisons and analysis (Table 1) . Literature data on the use of specific drugs during pregnancy, gestational age of the embryo or fetus during exposure to the drug, route of drug administration, absorption rate of the drug, whether the drug crosses the placenta, indication for the treatment, etc. were taken into account for each patient prior to final risk assessment. In compiling the clinical pharmacologists' expert opinion the following sources were used: British National Formulary [18] , AHFS Drug Information [19] , Briggs' Drugs in pregnancy and lactation [20] , Micromedex Database [21] , PubMed [22] search on the latest articles published on a specific topic. The FDA and ADEC categorisations are used as a general guideline, which was followed by an extensive literature search on drug safety of a specific drug, with the remark that all clinical pharmacologists working as consultants have more than 5 years' experience in the area of drug safety in pregnancy and have in-depth knowledge in this field of clinical pharmacology.
Statistical methods
Standard descriptive statistics were used to describe the study population, referral characteristics and pregnancy exposures. Means and standard deviations (SD) were calculated for continuous variables. For categorical data proportions were calculated and analysed using the maximum likelihood Chi-squared test. Statistical significance was set at p<0.05.
Associations with adverse pregnancy outcomes for FDA categorisation and clinical pharmacologists' risk assessment (on an NRS), age, parity, number of spontaneous abortions and number of prescribed drugs were evaluated using multiple logistic regression for continuous predictors, with adjusted odds ratios and 95% confidence intervals as the association measures, or where appropriate (for categorical variables: smoking, age group, previous pregnancies, and previous history of spontaneous abortions) by calculating odds ratios and its 95% confidence intervals for a 2×2 contingency Most consultations were with regard to drug exposure during pregnancy (95%); other consultations included therapy planning during this or future pregnancies, partners' drug exposure, diagnostic procedures, and other exposure-related problems during pregnancy.
For the purpose of this study, we further analysed only data on patients referred for consultations on pregnancy-related drug exposure (n=1,076). Patients were mostly referred for drug exposure during the first trimester of pregnancy (95%) and 84% of them were advised in their second month of pregnancy.
Most of the women were referred by a gynaecologist (89%), followed by general physicians (5%) and other specialists (4%; mostly neurologists and psychiatrists), and 2% of patients came on their own initiative.
Similar proportions of patients were consulted on drugs prescribed for the treatment of an acute condition (45%) and a chronic condition (41%). The mean number of drugs taken during pregnancy was 2.1 (range 1-9), and more than 50% of women were prescribed≥2 drugs. For more than 40% women this was their first pregnancy. The patients' demographic and referral characteristics are shown in Table 2 .
Drug exposure and risk assessment When exposure to individual drugs was taken into account most women were exposed to FDA category C (56%) and category B drugs (41%). When the highest FDA drug category among drugs prescribed to an individual patient was taken into account, most women were exposed to at least FDA category C (39%), followed by category D (30%) drugs. The exposure to high-risk FDA drugs (FDA DX) was high; 34% of pregnant women (466 women) were prescribed at least one FDA category D or X drug. When the FDA categorisation system was converted to a numerical scale (NRS 1-5), the mean risk assessment value in the studied population was 3.4 (SD ± 0.96). Fifty-seven women (5.4%) were exposed to medications with unknown pregnancy categories. Data on pregnancy-related drug exposure are summarised in Table 2 .
The clinical pharmacologists' risk assessment was available for all patients consulted on drug exposure during pregnancy. Estimation of high-risk exposure was recorded for 92 women (9%). On a numerical rating scale, the mean risk assessment value was 2.3 (SD ±0.71).
Clinical pharmacologists' risk assessment agreed with FDA risk categorisation in only 17% of FDA D drug exposures and 14% of FDA X drug exposures. In all other cases the clinical pharmacologists' risk assessment was lower, with the highest mean point difference of 2.2 within the FDA X group (Table 3) .
Clinical pharmacologists' risk assessment vs FDA classification with regard to available pregnancy outcomes Due to the high rate of patients lost to follow-up, pregnancy outcomes were available for only 516 pregnancies (48%). Starting in 2004, we organised more thoroughly the collection of follow-up data of advised patients using a more active approach (repeated phone calls and searching for potentially changed phone numbers or addresses in the case of failure, etc.). Most patients who were lost to followup were advised in the previous period, and were lost to follow-up due to the lack of information on, or changes in, patient's phone numbers, home address, etc.
There were no significant differences in age, referring physician, previous pregnancy, parity, history of spontaneous or induced abortions, number of prescribed drugs, the FDA's and clinical pharmacologists' risk classifications, and between women with available outcomes and women who were lost to follow-up. The only confounder that was more frequently present in the group of women with available pregnancy outcomes was smoking (30% vs 23%; p=0.012). Nevertheless, we conclude that women with available pregnancy outcomes are representative of the whole sample of 1,076 patients advised on pregnancyrelated drug exposure.
Four hundred and thirty-five healthy babies were delivered in 428 pregnancies; there were 46 cases of induced abortions, and 31 cases of spontaneous abortions; 8 women suffered other complications during pregnancy; and there were 3 cases of observed congenital malformations (1 major, 2 minor). After excluding induced abortions (46 cases) and exposure to medications not classified by the FDA (5 cases), 465 pregnancy outcomes were available for further analysis. We did not include cases of induced abortions, since they do not represent adverse pregnancy outcomes in the narrow sense, i.e. adverse outcome directly attributable to the use of a medication.
Both FDA and clinical pharmacologists' risk classifications were revealed to be significant predictors for adverse pregnancy outcomes. However, calculation of odds ratios (OR) confirmed a more significant association of clinical pharmacologists' risk assessment compared with FDA risk categorisation, both when using an NRS or proportions of those exposed to high-risk medications (Table 4) . Clinical pharmacologists' categorisation of pregnancy-related drug exposure to a high-risk group (NRS 4 and 5) had a better positive predictive value for adverse pregnancy outcomes compared with the FDA categorisation (25% vs 14% respectively), while the negative predictive values were similar (92% vs 94% respectively). Overall, clinical pharmacologists' risk estimation for the drug exposure studied was lower compared with the FDA risk categorisation.
Other risk factors associated with adverse pregnancy outcomes
Clinical pharmacologists' risk assessment was the strongest predictor of adverse pregnancy outcomes, whereas the number of drug exposures was not significantly related to adverse pregnancy outcomes. Other risk factors significantly associated with adverse pregnancy outcomes were age, concomitant diseases, previous pregnancies and parity. Cigarette smoking and number of drug exposures were not significantly associated with adverse pregnancy outcomes. Although the history of previous spontaneous abortions was not significantly related to adverse pregnancy outcomes, the number of previous spontaneous abortions increased the odds of an adverse pregnancy outcome. The calculated ORs for all evaluated risk factors and their confidence intervals are shown in Table 4 . 
Discussion
This study confirms significant differences in risk estimation between the FDA classification system and the clinical pharmacologists' risk assessment for pregnancy-related drug exposure, with an overall agreement in only 28% of cases. The FDA categorisation system gives only limited guidance to the prescribing physician, and many clinicians feel that despite the intent of the new labelling requirements to facilitate drug prescribing for pregnant patients, it has not lived up to original expectation in this regard [9] . It has been claimed that the FDA system is too simple and exerts confusion concerning gradation of risk across the categories. The second criticism of these categories is that they create an incorrect impression that the drugs within a given category represent similar reproductive risk. Among the drugs listed in the Physicians' Drug Reference, only 0.7% of drugs carry an FDA category A classification; 19% are in category B; 66% are in category C; 7% are in category D and 7% are in category X [23] . In response to these objections, the FDA made an announcement in May 2008, stating that they will replace the current A, B, C, D and X classification system with a narrative framework consisting of three major information parts: risk summary, clinical consideration and data. These changes were designed to facilitate informed counselling about and prescribing of medicines for women who are pregnant, breastfeeding, or of childbearing potential [11] . However, to date, the pregnancy risk categories are still in effect and are still being used by physicians.
Whether or not to prescribe a drug to a pregnant woman is a decision that must be made on an individual basis and includes a critical assessment of the available data from studies performed in animals and humans. Furthermore, there are numerous factors that should be taken into consideration: gestational age of the embryo or fetus during the exposure to the drug, the route of drug administration, and pharmacokinetic and pharmacodynamic characteristics of the drug [24] .
The evaluation of population characteristics in our study revealed a population under increased basal risk for adverse pregnancy outcomes, mainly due to the increased age, high prevalence of chronic conditions and exposure to high-risk drugs (FDA DX). The mean number of drugs prescribed to pregnant women in our study was similar or even lower than in studies exploring drug use during pregnancy [25] and comparable to a cross-sectional study that evaluated drug use in pregnant women in four of Zagreb's maternity hospitals (mean 2.6 drugs) [26] . However, the exposure of pregnant women included in our study to FDA category DX drugs was significantly higher when compared with the exposure in the general population of pregnant women (34% vs approximately 6-7%) [6, 27] . These findings were not surprising, and could be attributable to the tendency of other specialists to refer patients exposed to high-risk drugs to a clinical pharmacologist for further consultation, while patients exposed to drugs in lower risk categories consult within their own clinics. The prevalence of other risk factors was also considerable within the studied population; 51% of pregnant women were older than 30 years and 52% were suffering from a chronic condition. The percentage of women older than 30 years was higher than the Croatian average age of parturient women (40.4% in 2008) [28] . No data on the prevalence of chronic conditions among women of childbearing-age was available for Croatia, but data for the USA report that 9.9% of women of childbearing age have a chronic condition [29] . Twenty-seven percent of women were smokers, which is in agreement with Croatian statistics (approximately 30% of smokers among women) [30] . Approximately 40% of the women advised were in their first pregnancy, which is a slightly lower rate than the Croatian average (48% of first pregnancies) [31] .
Overall, clinical pharmacologists' risk estimation was in agreement with the FDA risk classification system in only 28% of consulted cases. Although 34% of patients were exposed to FDA category DX drugs, high-risk exposure according to a clinical pharmacologist's assessment was recorded in only 9% of patients (NRS 4 and 5). Percentages of A-X risk assessments by FDA risk classification and a clinical pharmacologist are shown in Fig, 1 . The rate of disagreement in estimation of risk of pregnancy-related drug OR odds ratio, CI confidence intervals exposure found in our study (72%) was higher than that recorded in a similar study that compared the differences in advice on drug safety in pregnancy between product monographs and five Drug Information Centres in Norway. The authors found a 47% difference in advice given on drug safety in pregnancy between these two sources of information, with information from the product monographs being significantly more restrictive [17] . This could be explained by the possibility of more accurate risk estimation in our study due to available data on all relevant risk factors, timing and dosage of drug exposure. Furthermore, the study mentioned did not include pregnancy outcomes. Subsequently, the question may be raised whether the less restrictive advice on drug safety in pregnancy was an understatement of risk and possibly resulted in more adverse pregnancy outcomes. Because of known difficulties associated with the assessments of the benefits and risks of drug therapy during pregnancy, there is a concern among prescribers about underestimating the risks of drug exposure especially during early pregnancy. The exclusive use of the FDA classification system could lead to overestimation of the risk, which may result in unnecessary withholding of beneficial therapy or in the termination of otherwise wanted pregnancies. This thesis is supported by our own experience; pregnant women are in some cases referred from other specialists for consultation with the aim of easing the decision for therapy cessation or patients' decision for pregnancy termination.
Despite the fact that in 72% of women included in our study the risk estimation was lower than that of the FDA risk classification system, adverse pregnancy outcomes in this group were not more frequent compared with the group with the same risk estimation (7.9% vs 11.8% respectively; p= 0.211; and 12.7% vs 20.0% in the FDA DX group, p=0.304).
The potential impact of differences in risk estimations can be illustrated by evaluating the distinctions in risk assessments within the FDA category X. The clinical pharmacologists' risk assessment was in agreement with the FDA risk classification system for only 21 out of 150 women with FDA category X exposure. In all other cases the risk estimation was lower. In everyday clinical practice, this difference could mean a significant decrease in numbers of potentially unnecessary induced pregnancy terminations. Indeed, after obtaining the clinical pharmacologists' expert opinion, only 10 out of 78 women with available outcomes (13%) exposed to FDA category X drugs considered the risk high enough to undertake an induced pregnancy termination. We can only assume that this number would be higher without the risk reassessment carried out by a clinical pharmacologist.
A good example is the use of oral contraceptives in early pregnancy. Although oral contraceptives are categorised as FDA category X drugs, available evidence does not support such a high-risk estimation for exposure during early pregnancy. There is no firm evidence linking oral contraceptives with any fetal anomalies except possible masculinisation of the female external genitalia. Exposure after 8 weeks' gestation would presumably be required for this effect to occur [32] . Out of 64 pregnancies with documented exposure to oral contraceptives during the first trimester of pregnancy with available outcomes, there were 52 pregnancies (81%) that resulted in delivery of a healthy child, 5 spontaneous abortions (8%), 4 induced abortions, 1 pregnancy complication (1.6%; a case of a preterm delivery) and 2 congenital anomalies (1 major and 1 minor congenital malformation). Both the rate of congenital malformations and the rate of spontaneous abortions in women exposed to oral contraceptives during the first trimester in our study were within expected rates (3% and 8% respectively).
The overall rate of congenital malformations in our study was 0.6% (3 out of 465), which is lower than the expected rate of congenital malformations within the general population of pregnant women in Europe (2.3%) according to data from the European Surveillance of Congenital Anomalies [33] . We have no obvious explanation for the low rate of congenital malformation recorded in our study. The rate of spontaneous abortions in our study was 6.2% (32 out of 465), which is was much lower than the expected rates of 10-15% [34, 35] . The rate of spontaneous abortions in Croatia is 15.9% [36] . This finding could be explained by the fact that most women were referred to us during the 2nd or 3rd month of pregnancy at a time point when some of the spontaneous abortions might have already occurred. The rate of women with previously legal abortion (9%) was also lower compared with the general population (19%) [35] . This could likely be attributed to underreporting due to unwillingness to provide information on previous induced abortions. We assessed the strength of association between both the clinical pharmacologists' risk assessment and the FDA risk categorisation, and adverse pregnancy outcomes. Risk estimation by a clinical pharmacologist was a better predictor of adverse pregnancy outcomes than the FDA risk classification. Despite the aforementioned limitations of the FDA risk classification system, our study results confirmed its general usefulness in risk estimation of pregnancy-related drug exposures. Hence with large numbers of false positives and few false negatives, the positive predictive values for adverse pregnancy outcomes were low; 14% for the FDA DX (or NRS 4 and 5) classification and 25% for the high-risk estimation by a clinical pharmacologist (NRS 4 and 5). This means that 14% of women exposed to FDA DX drugs during pregnancy will actually have an adverse pregnancy outcome, as well as 25% of women exposed to drugs classified by a clinical pharmacologist as being hazardous (NRS 4 and 5). The negative predictive value for adverse pregnancy outcome was similar for the two methods of risk classification (94% vs 92% respectively), which means that 94% and 92% of women classified as being exposed to lower-risk drugs will actually not have an adverse pregnancy outcome. Because of the lack of data from prospective controlled studies, it is rarely possible to precisely assess the risks of medication use during pregnancy, thus the positive predictive value of any available method of risk estimation of pregnancy-related drug exposure is expected to be low. From a legal and ethical point of view, it is often safer for drug manufacturers and prescribers to overestimate than underestimate potential risks. Nevertheless, women must receive accurate and updated information, as an unrealistic perception of risk may lead to unnecessary terminations of otherwise wanted pregnancies or inadequate treatment of maternal disease.
Other already established risk factors that were confirmed as being significantly associated with the occurrence of adverse pregnancy outcomes in our study were: age [37] , concomitant chronic disease [38, 39] , history of previous pregnancies and number of previous pregnancies [40] .
The most reliable information on drug safety in pregnancy is derived from large population-based pregnancy registries, like the Norwegian [41] or Swedish Medical Birth Registers [42] , which include data on practically all deliveries in Sweden. Although the most important advantage of such databases is their size, there are some limitations: reporting bias (underreporting of drug use, the interviewer's lack of interest in collecting all the information, etc.), no precise information on dosage and timing of drug use and lack of accurate data on underlying diseases. The most important advantages of our study are accurate information on the drug dosage and timing of drug exposure, data on confounders, and a low reporting bias regarding medication use, since the women were referred specifically for that reason. The limitations are the small sample size and a large number lost to follow-up.
To the best of our knowledge, this is the first study to examine differences between the FDA risk classification and risk assessment carried out by a clinical pharmacologist (or another expert) that included pregnancy outcomes of the women advised. Consequently, better positive predictive value of adverse pregnancy outcomes of a clinical pharmacologists' risk assessment compared with the sole use of the FDA risk classification system, suggests the important role of a trained expert as a corrector of drug classification systems and in providing reliable information for other prescribers as well as pregnant women, thus contributing to better resolution of numerous safety issues of drug therapy during pregnancy.
In conclusion, assessing the risk of pregnancy-related drug exposure is time-consuming and requires good knowledge of drug pharmacokinetics and pharmacodynamics, epidemiology, teratology as well as training and experience in the critical assessment of published data. Clinical pharmacologists who have undergone rigorous medical training are ideally placed to consult on administration of medicines in pregnant women, thus making the prescribing of treatments in that patient category substantially safer and more rational.
